Detail akcie Oasmia Pharma online

Business Summary: Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Vivesto AB revenues decreased from SEK1M to SEK0K. Net loss decreased 65% to SEK128.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Depreciation/Amortization decrease of 78% to SEK57.4M (expense), Other external expenses decrease of 13% to SEK50.8M (expense).